Digestery
Longevity supplements › Resveratrol and Aging › Studies

Randomized trial · measured lab tests or safety

A 24-month trial in postmenopausal women found resveratrol raised bone density in the spine

Wong and colleagues · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020

Original title: Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo-Controlled Trial.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

After 12 months, bone density rose in the lumbar spine (+0.016 ± 0.003 g/cm2) and femoral neck (+0.005 ± 0.002 g/cm2). A bone breakdown marker fell 7.24% vs placebo.

The study at a glance

Type of study
Randomized trial
Who or what was studied
Postmenopausal women without bone disease
What was tested
Resveratrol 75 mg twice daily vs placebo, each for 12 months, then switched (24-month crossover)
What it measured
Lab tests or markers
Daily amount
150 mg a day
How long
104 weeks
Who has a stake
No disclosure in PubMed
No disclosure in PubMed.
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2020
Source
PubMed record 32564438. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • •The abstract does not say how many people took part.
  • ✓Long: about 2 years.
  • –Measured lab tests or markers, which stand in for aging and age-related disease. A better marker does not always mean better health.
  • •The PubMed record has no conflict-of-interest statement.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    3

    1 benefit, 1 mixed, 1 no difference

  2. Trials in people: other measures

    3

    1 benefit, 1 mixed, 1 harm

  3. Trials in people: lab tests or safety

    7

    4 benefit, 2 mixed, 1 no difference

    ↑ This study is the ringed dot

  4. Population studies

    1

    1 benefit

  5. Blood levels and genes

    1

    1 no difference

  6. Animals

    1

    1 benefit

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does resveratrol slow aging?”

Not shown in people.

Confidence: very low. Based on 22 on-topic papers.

Read the full answer

Of the other 6 papers on the same step: 3 benefit, 2 mixed, 1 no difference. This one found benefit.

Other papers on the same step

See all 22 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.